two special lectures, one education lecture, one roundtable-style commemorative session on the LCSGJ's history, three symposia, seven panel discussions, nine workshops, six video sessions, six difficult clinical case study sessions, and two consensus meetings ( table 1 ) .
In Symposium 1 entitled 'Basic Aspect, Diagnosis, Treatment, and Prognosis of Early Hepatocellular Carcinoma', discussions were held on next-generation sequencing analysis and diagnostic imaging for early hepatocellular carcinoma (HCC) [5] , diagnosis by Sonazoidenhanced ultrasonography and gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid MRI, issues associated with pathological diagnosis, and the timing of treatment. Symposium 2 provided a forum for discussion in line with the session 'Treatment Strategies for Advanced and Large Liver Cancer' and particularly the attempts to Extracted sentences from an article published in Archives of Surgery [4] . Dr. Foster Latest diagnostic imaging modalities [6] [7] [8] [9] were introduced in Panel Discussion 1, entitled 'Innovation in Diagnostic Imaging for Liver Cancer', while basic research approaches using, for example, oncogenes and methylation were discussed in Panel Discussion 2 on 'Future Prospects in Liver Cancer Treatment Based on Genome/Epigenome Data'. In Panel Discussion 3 on 'Future Perspectives on Molecular Targeted Therapy for Liver Cancer', discussions centered around the application of molecular targeted therapy, for which sorafenib is currently the only approved drug, the combination of sorafenib with conventional locoregional treatments [10] [11] [12] [13] [14] [15] [16] [17] [18] , and other emerging targeted agents. Nine workshops were held at the congress. In Workshop 1 on 'Treatment for Child-Pugh C Liver Cancer', it was verified that locoregional therapy confers survival benefit to a specific subgroup of liver cancer patients with Child-Pugh C liver function. The discussions in Workshop 2 entitled 'Treatment Strategies for Recurrent Liver Cancer after Liver Transplantation' focused on recurrence, the most serious problem caused by liver transplantation [19] [20] [21] [22] [23] . In Workshop 3, the mechanism of and clinical approach to nonalcoholic steatohepatitis (NASH)-induced liver cancer were discussed under the theme of 'Basic and Clinical Aspects of NASHInduced Liver Cancer: Including Diagnostic Criteria' [24] . Workshop 4 on 'Long-term Survival Cases ( ≥ 3 Years) of Advanced Hepatocellular Carcinoma after the Initiation of Molecular Targeted Therapy' focused on the characteristics of long-term survival cases after treatment with sorafenib. In Workshop 5 on 'Treatment Strategy for Intrahepatic Cholangiocarcinoma', surgical outcome of intrahepatic cholangiocarcinoma and the characteristics of recurrence were discussed with a focus on hepatectomy. Workshop 6 focused on 'Radiation Therapy for Hepatocellular Carcinoma', and the participants discussed treatment directed solely at vascular invasion or the main lesion of HCC itself and proton and particle therapy [25, 26] . In addition, under the theme 'Treatment Strategy for Colorectal Liver Metastasis' in Workshop 7, the participants engaged in an active discussion of systemic chemotherapy, surgical approaches, microwave coagulation therapy, radiofrequency ablation (RFA), or particle therapy as locoreginal treatments.
The main focus in Workshop 8, entitled 'Current Situation and Recent Advances in RFA' was bipolar RFA, and new RFA techniques including fusion image-guided RFA were also discussed [27] . Lastly, in Workshop 9 entitled 'New Developments in TACE: How to Apply Beads TACE and cTACE Differently', the participants discussed the differential application of conventional TACE [28] and beads (microsphere) TACE, the latter of which was introduced to Japan in January 2014.
In Video Session 1 entitled 'State-of-the-Art Contrast-Enhanced Ultrasonography', the significance of As a special program, a roundtable-style presentation was held under the title 'Looking Back on the 50-Year History of the Liver Cancer Study Group of Japan', and eight professors who had led the LCSGJ through the last 50 years introduced the history of the LCSGJ to the younger generation of LCSGJ members. This special program also provided a great opportunity to think about how we should develop the LCSGJ over the next 50 years.
In the Education Lecture, Prof. Kazuto Nishio gave a speech about 'Biomarkers in Molecular Targeted Therapy for Liver Cancer', which provided up-to-date information on biomarkers. In addition, Prof. Hidemi Kumai and Prof. Markus Peck presented highly relevant Special Lectures on 'Full Lifecycle Aquaculture of Bluefin Tuna: 32-Year Trajectory' and 'Management of Liver CancerWhy We Do What We Do in Europe', respectively. Two consensus meetings organized by the LCSGJ turned out to be the highlight of the 50th Congress. In Consensus Meeting 1 on 'A Diagnostic Algorithm for Liver Cancer', liver cancer experts used a voting system to decide on an updated version of the consensus-based diagnostic algorithm proposed by the Japan Society of Hepatology (JSH) [29] . In Consensus Meeting 2 on 'Updating the JSH Definition of TACE Failure/Refractoriness', experts decided to revise the definition [29] .
The 50th LCSGJ Congress drew over 1,200 attendees over 2 days and was a great success. In this supplementary issue of Oncology , some of the articles discuss the sessions held at the congress, making it an extremely valuable special issue for readers specializing in liver cancer.
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